Markets

Health Care Sector Update for 04/03/2017: NVCR,CYCC,EKSO

Top Health Care Stocks

JNJ -0.06%

PFE -0.23%

MRK -0.69%

ABT -0.31%

AMGN -0.24%

Health care stocks were narrowly lower in recent trade, with the NYSE Health Care Index declining less than 0.1% while shares of health care companies in the S&P 500 were down nearly 0.2% as a group.

In company news, Novocure Ltd ( NVCR ) rallied Monday after the specialty drugmaker today reported positive results from Phase III testing of a combination of its Optune product candidate plus temozolomide in 695 patients with a form of brain cancer.

The survival rate for glioblastoma patients treated with the drug combination increased from 30% to 43% after two years and rose from 5% to 13% of the patients after five years, which were the best results reported so far for newly diagnosed glioblastoma patients during late-stage testing.

NVCR shares were up more than 44% at $11.70 apiece, earlier topping out at $14.30 a share.

In other sector news,

(+) CYCC, (+58.9%) Presents positive data for CYC065 drug candidate, saying the second-generation, cyclin-dependent kinase 2/9 inhibitor substantially inhibited growth and triggered apoptosis in murine and human lung cancer cells.

(-) EKSO, (-17.8%) Prices $11.6 mln private placement of 3.7 mln shares of common stock at a price of $3.14 apiece. Deal also includes warrants to buy up to nearly 1.9 mln additional shares at $4.10 each.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

NVCR CYCC EKSO

Other Topics

US Markets